Deciphera Pharmaceuticals (DCPH) Posts Earnings Results, Misses Estimates By $0.13 EPS

Deciphera Pharmaceuticals (NASDAQ:DCPH) released its quarterly earnings data on Thursday. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.13), Fidelity Earnings reports.

Shares of DCPH stock opened at $25.50 on Friday. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -8.53 and a beta of 3.27. Deciphera Pharmaceuticals has a 1 year low of $18.55 and a 1 year high of $45.61. The company has a current ratio of 18.46, a quick ratio of 18.46 and a debt-to-equity ratio of 0.06.

In related news, Director James Arthur Bristol sold 18,883 shares of the stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $28.04, for a total value of $529,479.32. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Thomas Patrick Kelly sold 1,500 shares of the stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $30.00, for a total value of $45,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 198,426 shares of company stock worth $5,247,846. Insiders own 20.61% of the company’s stock.



A hedge fund recently raised its stake in Deciphera Pharmaceuticals stock. Geode Capital Management LLC raised its stake in shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) by 19.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 166,904 shares of the company’s stock after acquiring an additional 27,157 shares during the quarter. Geode Capital Management LLC owned approximately 0.44% of Deciphera Pharmaceuticals worth $3,503,000 at the end of the most recent reporting period. 57.28% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently commented on DCPH. Zacks Investment Research downgraded Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. BidaskClub upgraded Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 2nd. Leerink Swann decreased their target price on Deciphera Pharmaceuticals from $28.00 to $20.00 and set an “underperform” rating on the stock in a research report on Friday, November 16th. Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 target price on shares of Deciphera Pharmaceuticals in a research report on Thursday, December 20th. Finally, B. Riley downgraded Deciphera Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. Deciphera Pharmaceuticals has an average rating of “Buy” and an average target price of $42.67.

COPYRIGHT VIOLATION WARNING: “Deciphera Pharmaceuticals (DCPH) Posts Earnings Results, Misses Estimates By $0.13 EPS” was published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://dakotafinancialnews.com/2019/03/15/deciphera-pharmaceuticals-dcph-posts-earnings-results-misses-estimates-by-0-13-eps.html.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Read More: QQQ ETF

Earnings History for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.